Acute Kidney Injury: Preclinical Innovations, Challenges, and Opportunities for Translation

Canadian Journal of Kidney Health and Disease - 2015
Samuel A. Silver1, Héloïse Cardinal2, Katelyn Colwell3, Dylan Burger4, Jeffrey G. Dickhout5
1Division of Nephrology, St. Michael’s Hospital, University of Toronto, Toronto, Canada
2Division of Nephrology, Centre Hospitalier de l'Université de Montréal and CHUM research center, Montreal, Quebec, Canada
3Department of Medicine, Division of Nephrology, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
4Kidney Research Centre, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
5Department of Medicine, Division of Nephrology, McMaster University and St. Joseph's Healthcare Hamilton, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada

Tóm tắt

Background: Acute kidney injury (AKI) is a clinically important condition that has attracted a great deal of interest from the biomedical research community. However, acute kidney injury AKI research findings have yet to be translated into significant changes in clinical practice. Objective: This article reviews many of the preclinical innovations in acute kidney injury AKI treatment, and explores challenges and opportunities to translate these finding into clinical practice. Sources of Information: MEDLINE, ISI Web of Science Findings: This paper details areas in biomedical research where translation of pre-clinical findings into clinical trials is ongoing, or nearing a point where trial design is warranted. Further, the paper examines ways that best practice in the management of AKI can reach a broader proportion of the patient population experiencing this condition. Limitations: This review highlights pertinent literature from the perspective of the research interests of the authors for new translational work in AKI. As such, it does not represent a systematic review of all of the AKI literature. Implications: Translation of findings from biomedical research into AKI therapy presents several challenges. These may be partly overcome by targeting populations for interventional trials where the likelihood of AKI is very high, and readily predictable. Further, specific clinics to follow-up with patients after AKI events hold promise to provide best practice in care, and to translate therapies into treatment for the broadest possible patient populations.

Từ khóa


Tài liệu tham khảo

10.2215/CJN.00710113

10.1016/S0140-6736(11)61454-2

10.2215/CJN.12101112

10.1681/ASN.2004090740

10.1038/ki.2011.379

10.1681/ASN.2012111115

10.1172/JCI72269

10.1681/ASN.2012080784

10.1681/ASN.2013070718

10.1172/JCI37829

10.1017/erm.2014.14

10.1152/ajprenal.00643.2013

10.1681/ASN.2013090952

10.1254/jphs.08272SC

10.1016/j.ejphar.2008.06.108

10.1093/toxsci/kfm152

10.1016/j.tiv.2007.03.001

10.1089/ars.2009.2705

10.1371/journal.pone.0084663

10.1161/CIRCRESAHA.110.226803

10.1046/j.1523-1755.2001.0590051798.x

10.1152/ajprenal.00482.2011

10.1111/bcpt.12973

10.1038/nrneph.2011.16

10.1089/omi.2009.0073

10.1016/j.bbrc.2007.12.098

10.1002/hep.26611

10.1006/mthe.2002.0639

10.2174/1871529X1401140724093505

10.1016/j.semnephrol.2004.04.003

10.1152/ajprenal.00546.2010

10.1152/ajprenal.90276.2008

10.1038/sj.ki.5002312

10.1093/ndt/gft488

10.1084/jem.20050390

10.1096/fj.03-0573fje

10.1111/ajt.12168

10.1053/j.ajkd.2012.08.034

10.1093/ndt/gfs556

10.4061/2011/828369

10.1111/nep.12018

10.1161/CIRCULATIONAHA.109.928796

10.3727/096368912X636902

10.1152/ajprenal.00485.2009

10.1152/ajprenal.00329.2001

10.1093/ndt/gfs110

10.5301/jn.5000255

10.1159/000353233

10.5966/sctm.2012-0114

10.1155/2013/732742

10.1159/000360667

10.1681/ASN.2007020140

10.1152/ajprenal.00594.2010

10.1042/CS20120309

10.1038/ki.2012.105

de Almeida DC, 2013, Clin Biochem Rev, 34, 131

10.1016/j.transproceed.2006.12.019

10.1093/molehr/gah129

10.1186/1479-5876-6-37

10.2215/CJN.12191213

10.1164/rccm.201401-0077OC

10.1186/cc12503

10.1097/01.ASN.0000093254.31868.85

10.1016/S0272-6386(98)70073-3

10.1111/ajt.12210

10.1053/j.ajkd.2012.11.050

10.1111/tri.12217

10.1093/ndt/gfn667

10.1097/TP.0b013e3182855544

10.1056/NEJMoa060068

10.5489/cuaj.1147

10.1111/j.1600-6143.2010.03179.x

10.1111/ctr.12135

10.1111/j.1600-6143.2011.03810.x

10.1111/j.1440-1797.2006.00532.x

10.1038/ki.2014.188

10.1097/01.tp.0000256336.48046.b1

10.1056/NEJMoa0802289

10.1002/bjs.9169

10.1371/journal.pone.0081826

10.1371/journal.pone.0056368

10.3310/hta13380

10.1056/NEJMoa0902413

10.1056/NEJMoa0802639

Disease K, 2012, KDIGO Clinical Practice Guideline for Acute Kidney Injury Kidney Int Suppl, 2, 1

10.1038/ki.2012.451

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013, Kidney Int Suppl, 3, 1, 10.1038/kisup.2012.73

10.1016/j.cjca.2014.02.002

10.1016/j.cjca.2012.11.032

Disease K, Improving Global Outcomes (KDIGO) Lipid Work Group, 2013, Kidney Int Suppl, 3, 259, 10.1038/kisup.2013.27

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2013, Can J Diabetes, S1

10.1056/NEJMra1214243

10.1681/ASN.2011030315

Arora P, 1999, J Am Soc Nephrol, 10, 1281, 10.1681/ASN.V1061281

10.1093/ndt/gfs431

10.1093/ndt/gfq843

10.1016/j.amjmed.2011.04.026

10.1007/s11606-010-1523-6

10.1001/archinte.162.17.2002

10.1001/archinte.165.16.1842

10.1503/cmaj.045311

10.1001/jama.2011.1206

10.1681/ASN.2013060610

10.2215/CJN.02440213

10.1038/ki.2011.405

10.1136/bmj.321.7262.694

10.1681/ASN.2013040359

10.1038/ki.2011.198

10.1038/ki.2011.42

10.1186/1471-2369-15-114

10.1097/01.ACM.0000225223.45701.da

Thông tin
Thông tin xuất bản

Canadian Journal of Kidney Health and Disease

Thông tin tác giả